Related Experiment Video
Updated: Jun 22, 2026
Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus
Published on: May 13, 2021
Analysis of HSV oncolytic virotherapy in organotypic cultures
1Brain Tumor Research Center, Simches Research Building, Neurosurgery Service, Massachussetts General Hospital, Boston, MA, USA.
Abstract:
Tumor-selective replication-competent viral vectors, such as oncolytic herpes simplex virus (HSV) type I (HSV-1), represent an attractive strategy for tumor-based therapies because these viruses can replicate and spread in situ exhibiting cytopathic effects through direct oncolytic activity. These lytic viruses offer a distinct advantage over other forms of cancer therapies in that they are self-perpetuating and can spread not only in the tumor itself, but also to distant micrometastases. Translational studies aimed at identifying novel virotherapies for human cancers are incumbent upon the appropriate experimental models. While animal models are the preferred choice for efficacy studies of HSV virotherapy, we have developed a novel complementary approach toward assessing the effectiveness of oncolytic HSV therapy in both brain and prostate cancers. This experimental model takes advantage of previously published work in which human prostate cancer biopsies and rodent brain slices can be easily maintained ex vivo. The advantage of these systems is that the three-dimensional structure remains intact. Thus, all of the factors that may affect viral entry and replication, such as cell-cell and cell-matrix interactions, and interstitial fluid within this three-dimensional milieu remain preserved. Moreover, with respect to the brain, this system offers the advantage of direct access to brain cells, such as microglia and astrocytes, and circumvents the problems associated with the presence of the blood-brain barrier.
Insights
Oncolytic herpes simplex virus (HSV) offers a promising cancer therapy. Researchers developed a novel ex vivo model using human prostate cancer biopsies and rodent brain slices to assess HSV effectiveness in brain and prostate cancers.
Area of Science:
- Oncolytic virotherapy
- Cancer research
- Virology
Background:
- Oncolytic herpes simplex virus (HSV) type I exhibits tumor-selective replication and direct cytopathic effects.
- These self-perpetuating viruses can spread within tumors and to micrometastases, offering a therapeutic advantage.
- Effective translational studies for HSV virotherapy require appropriate experimental models.
Purpose of the Study:
- To develop and assess a novel complementary experimental model for evaluating oncolytic HSV therapy.
- To investigate the effectiveness of oncolytic HSV in both brain and prostate cancers.
- To provide an alternative to animal models for HSV virotherapy efficacy studies.
Main Methods:
- Utilized previously established methods for maintaining human prostate cancer biopsies ex vivo.
- Employed rodent brain slices for ex vivo maintenance, preserving three-dimensional structure.
- Assessed oncolytic HSV effectiveness in these ex vivo models, maintaining cell-cell and cell-matrix interactions.
Main Results:
- The ex vivo model preserves the three-dimensional tissue structure, crucial for studying viral entry and replication.
- This model allows direct access to brain cells like microglia and astrocytes, bypassing the blood-brain barrier.
- The model provides a viable complementary approach to animal studies for assessing oncolytic HSV efficacy.
Conclusions:
- The developed ex vivo model serves as a valuable tool for assessing oncolytic HSV therapy in prostate and brain cancers.
- This approach maintains critical biological factors influencing viral behavior in a 3D context.
- It offers a complementary strategy to animal models, facilitating translational research in cancer virotherapy.
